Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Diabetic Ulcers
Interventions: Vasculera; Dietary Supplement
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 25 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers, Non Healing Wound
Interventions: Timolol, Non biologically active gel; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Ulcerative Colitis
Interventions: Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 48
States / cities: Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 41 more

Conditions: Ulcer Venous, Wound Heal
Interventions: InnovaMatrix® AC Sterilized, Porcine Placental Extracellular Matrix (ECM); Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Colitis, Ulcerative
Interventions: Spesolimab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 8
States / cities: Hamden, Connecticut • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Spinal Cord Injuries
Interventions: SCI Virtual Coach; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Systemic Sclerosis, Scleroderma
Interventions: treprostinil diethanolamine, placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 24
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 21 more

Conditions: Ulcerative Colitis
Interventions: CP-690,500 5 mg, CP-690,550 10 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 24
States / cities: Mobile, Alabama • San Diego, California • Bristol, Connecticut + 14 more

Conditions: Diabetic Foot Ulcer
Interventions: NuShield; Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Carlsbad, California • Fresno, California • Los Angeles, California + 6 more

Conditions: Venous Disease
Interventions: sodium tetradecyl sulfate, Compression; Drug · Device
Lead sponsor: Ellen Dillavou; Other
Eligibility: 18 Years to 100 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Foot Ulcer, Ulcer, Diabetic Foot Ulcer, Wound, Wound Heal
Interventions: No interventions; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 4
States / cities: Indianapolis, Indiana • Columbus, Ohio

Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions: Digital self-management program, Standard Care; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Foot Ulcer, Diabetic Foot
Interventions: Collagenase ointment, Modified Contact Cast System; Drug · Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Colitis, Ulcerative
Interventions: Guselkumab Dose 1, Guselkumab Dose 2, Golimumab Dose 1, Golimumab Dose 2, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 14
States / cities: San Diego, California • Colorado Springs, Colorado • Tampa, Florida + 11 more

Conditions: Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Head and Neck Cancer
Interventions: Photobiomodulation, Routine Oral Care and Analgesia; Device · Other
Lead sponsor: MuReva Phototherapy Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: Birmingham, Alabama • Long Beach, California • Miami, Florida + 9 more

Conditions: Healthy Volunteer, Pressure Distribution
Interventions: Bed A - Head of Bed 0 degrees, Bed B - Head of Bed 0 degrees, Bed A - Head of bed at 30 degrees, Bed B - head of bed at 30 degrees; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Colitis, Ulcerative
Interventions: Trichuris suis ova (TSO), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 17
States / cities: Palo Alto, California • New Haven, Connecticut • Miami, Florida + 13 more

Conditions: Upper Gastrointestinal Hemorrhage
Interventions: Over-the-scope hemoclipping device, Standard endoscopic treatment; Device · Other
Lead sponsor: CURE Digestive Diseases Research Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Venous Leg Ulcers
Interventions: NuShield®; Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pickerington, Ohio

Conditions: Ulcers, Bedsores
Interventions: Mapping System, Non-Mapping System; Device
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions: Bezlotoxumab, Placebo, Fecal Microbiota Transplantation; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ulcerative Colitis
Interventions: Fecal Microbiota Transplantation; Biological
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Pressure Ulcer
Interventions: PUMP Monitoring; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetic Foot Ulcer (DFU), Ulcer Foot, Diabetic Foot, Foot Ulcer
Interventions: Standard of Care, Revita, Relese, Cogenex, Enverse; Other
Lead sponsor: StimLabs; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Omaha, Nebraska • Tulsa, Oklahoma • Jefferson Hills, Pennsylvania + 2 more

Search by objective public record fields.

Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers

Beta Adrenergic Antagonist for the Healing of Chronic DFU

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Observational Study to Investigate the Use of Sterilized Porcine Placental Tissue in the Treatment of Chronic VLU

BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis

Spinal Cord Injury Virtual Coach RCT

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

Perforator Vein Injection for Symptomatic Venous Disease

miR-200b & miR-21 in Diabetic Wounds

Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease

EZCast-DFU Study With Portal for Application of Topical Medications

A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

Comparison of Sacral Interface Pressure in Healthy Volunteers on Two Dynamic Pressure-Prevention Support Surfaces

Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis

Standard Endoscopic Hemostasis Versus OVESCO Severe Non-variceal UGI Hemorrhage

Clinical Trial Evaluating NuShield® Plus Standard of Care (SOC) Versus Standard of Care (SOC) Alone in the Management of Non-Healing Venous Leg Ulcers (VLUs)

Utility of Interface Pressure Mapping

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis (UC)

Pressure Ulcer Monitoring Platform (PUMP)

Modified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs